Group items tagged

2007 Task Force Report on Aging Research Funding

Download - Adobe Acrobat (PDF), 1.37 MB

The 2007 Task Force on Aging Research Funding--more than 85 non-partisan disease groups, patient advocates, and foundations--urges Congress and the President to chart a better course for medical research on behalf of America's aging population. This year's report of the Task Force calls for a 6.7% increase in funding for the National Institutes of Health in FY 2008. It also presents data on the burden of 27 diseases and conditions that predominately affect older Americans, highlights some of the exciting work the NIH is doing to decrease these burdens, and serves as a resource for policymakers working to establish the funding levels necessary to advance healthy aging.

transcripts of a Congressional forum on March 17, 2003

With the impending age boom in 2010, our nation must have a healthcare system in place that is prepared for the millions of Americans who will be living with chronic diseases, and that is able to foster the development of future treatments to meet their needs.

Download - Adobe Acrobat (PDF), 1.64 MB

FDA is a scientific bureaucracy with police powers. Patients and physicians are free to choose only those drugs and medical devices that it has approved. When FDA approves a therapy that later turns out to be unexpectedly risky, the agency is the subject of front-page headlines and congressional hearings. On the other hand, when FDA delays a badly needed new therapy, patients will suffer but hardly anyone will blame FDA.

Consider, for example, FDA's 10-year delay, in 1967-76, in approving beta-blockers to prevent death following heart attacks, because of the agency's fear that the drugs might be carcinogenic. During those years, the drugs saved lives in Europe and elsewhere, while an estimated 10,000 heart attack victims unnecessarily died in this country each year. When beta blockers were finally approved in the US, to wide acclaim, hardly anyone raised the lethal effects of FDA's slowness.

As it turns out, however, that extra agency caution doesn't actually improve drug safety. Studies conducted by FDA itself show that the rate of drug withdrawals has remained essentially unchanged over the last 25 years, despite rising and falling approval times during that period.

The National Institute on Aging (NIA) is a division of the U.S. National Institutes of Health (NIH), located in Bethesda, Maryland. The NIA leads a broad scientific effort to understand the nature of aging and to extend the healthy, active years of life. In 1974, Congress granted authority to form NIA to provide leadership in aging research, training, health information dissemination, and other programs relevant to aging and older people. Subsequent amendments to this legislation designated the NIA as the primary Federal agency on Alzheimer's disease research.

In March 1966, NASA told Congress the "run-out cost" of the Apollo program to put men on the moon would be an estimated $22.718 Billion for the 13-year program which eventually accomplished six successful missions between July 1969 and December 1972. According to Steve Garber, the NASA History website curator, the final cost of project Apollo was between $20 and $25.4 billion in 1969 dollars (or approximately $135 billion in 2005 dollars). The costs associated with the Apollo spacecraft and Saturn rockets amounted to about $83 billion [Apollo spacecraft: $28 billion (Command/Service Module: $17 billion; Lunar Module: $11-billion), Saturn I, Saturn IB, Saturn V launch vehicles: about $46 billion] in 2005 dollars.

Dr. Miller formerly led business operations for the global Drug Discovery Division at pharmaceutical company Glaxo Smith Kline.

Well one thing that I think is going to be critical is that in the past, pharmaceutical companies had treated diseases of aging as discrete entities, that is to develop something for diabetes, to develop something for osteoporosis…that is to treat each one as a separate silo if you will.

in the future we are going to have to look at more central regulatory pathways that are being identified now for aging.